dpp-4 inhibitors vs. glp-1 agonist receptor versus inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes Cardiovascular effects of DPP-4 inhibition:
Description
doi: 10.1111/obr.13046 143 SetjiTLBrownAJ
doi: 10.1111/dom.12849 32 SimRChongCWLoganadanNKFongAYYNavaravongLHusseinZet al
& Greig, N
These results are the basis for a positioning of the DPP-4 inhibitors as second-line therapy for the treatment of type 2 diabetes, especially, when hypoglycaemia should strictly be avoided (see section below)
Materials and Methods Study Design and Setting This retrospective study utilized prospectively collected data from patients treated at our bariatric surgery center between January 2019 and October 2023
We're not there yet with obesity or obesities
